BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 20485525)

  • 1. Second generation sequencing of the mesothelioma tumor genome.
    Bueno R; De Rienzo A; Dong L; Gordon GJ; Hercus CF; Richards WG; Jensen RV; Anwar A; Maulik G; Chirieac LR; Ho KF; Taillon BE; Turcotte CL; Hercus RG; Gullans SR; Sugarbaker DJ
    PLoS One; 2010 May; 5(5):e10612. PubMed ID: 20485525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptome sequencing of malignant pleural mesothelioma tumors.
    Sugarbaker DJ; Richards WG; Gordon GJ; Dong L; De Rienzo A; Maulik G; Glickman JN; Chirieac LR; Hartman ML; Taillon BE; Du L; Bouffard P; Kingsmore SF; Miller NA; Farmer AD; Jensen RV; Gullans SR; Bueno R
    Proc Natl Acad Sci U S A; 2008 Mar; 105(9):3521-6. PubMed ID: 18303113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentially expressed alternatively spliced genes in malignant pleural mesothelioma identified using massively parallel transcriptome sequencing.
    Dong L; Jensen RV; De Rienzo A; Gordon GJ; Xu Y; Sugarbaker DJ; Bueno R
    BMC Med Genet; 2009 Dec; 10():149. PubMed ID: 20043850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next generation mapping reveals novel large genomic rearrangements in prostate cancer.
    Jaratlerdsiri W; Chan EKF; Petersen DC; Yang C; Croucher PI; Bornman MSR; Sheth P; Hayes VM
    Oncotarget; 2017 Apr; 8(14):23588-23602. PubMed ID: 28423598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma.
    Mansfield AS; Peikert T; Smadbeck JB; Udell JBM; Garcia-Rivera E; Elsbernd L; Erskine CL; Van Keulen VP; Kosari F; Murphy SJ; Ren H; Serla VV; Schaefer Klein JL; Karagouga G; Harris FR; Sosa C; Johnson SH; Nevala W; Markovic SN; Bungum AO; Edell ES; Dong H; Cheville JC; Aubry MC; Jen J; Vasmatzis G
    J Thorac Oncol; 2019 Feb; 14(2):276-287. PubMed ID: 30316012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-occurring Mutations of Tumor Suppressor Genes,
    Tranchant R; Quetel L; Tallet A; Meiller C; Renier A; de Koning L; de Reynies A; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
    Clin Cancer Res; 2017 Jun; 23(12):3191-3202. PubMed ID: 28003305
    [No Abstract]   [Full Text] [Related]  

  • 7. Chromosomal deletion in patients with malignant pleural mesothelioma.
    Neragi-Miandoab S; Sugarbaker DJ
    Interact Cardiovasc Thorac Surg; 2009 Jul; 9(1):42-4. PubMed ID: 19346221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormalities of chromosomes 7 and 22 in human malignant pleural mesothelioma: correlation between Southern blot and cytogenetic analyses.
    Tiainen M; Kere J; Tammilehto L; Mattson K; Knuutila S
    Genes Chromosomes Cancer; 1992 Mar; 4(2):176-82. PubMed ID: 1373319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas.
    Kang HC; Kim HK; Lee S; Mendez P; Kim JW; Woodard G; Yoon JH; Jen KY; Fang LT; Jones K; Jablons DM; Kim IJ
    Oncotarget; 2016 Feb; 7(7):8321-31. PubMed ID: 26824986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: possible sites of tumor suppressor genes.
    Flejter WL; Li FP; Antman KH; Testa JR
    Genes Chromosomes Cancer; 1989 Nov; 1(2):148-54. PubMed ID: 2487155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of actionable mutations in malignant pleural mesothelioma.
    Shukuya T; Serizawa M; Watanabe M; Akamatsu H; Abe M; Imai H; Tokito T; Ono A; Taira T; Kenmotsu H; Naito T; Murakami H; Takahashi T; Endo M; Ohde Y; Nakajima T; Yamamoto N; Koh Y
    Lung Cancer; 2014 Oct; 86(1):35-40. PubMed ID: 25174276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32.
    Taniguchi T; Karnan S; Fukui T; Yokoyama T; Tagawa H; Yokoi K; Ueda Y; Mitsudomi T; Horio Y; Hida T; Yatabe Y; Seto M; Sekido Y
    Cancer Sci; 2007 Mar; 98(3):438-46. PubMed ID: 17270034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-based Mutational Analysis by Next Generation Sequencing in Patients with Malignant Pleural and Peritoneal Mesothelioma.
    Ugurluer G; Chang K; Gamez ME; Arnett AL; Jayakrishnan R; Miller RC; Sio TT
    Anticancer Res; 2016 May; 36(5):2331-8. PubMed ID: 27127140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
    Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
    Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression and clinical significance of SETD2 in maligant pleural mesothelioma].
    Yu M; Yu M; Zhu LJ; Yuan XY; Zhang X
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb; 39(2):91-98. PubMed ID: 33691361
    [No Abstract]   [Full Text] [Related]  

  • 16. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
    Cheng YY; Kirschner MB; Cheng NC; Gattani S; Klebe S; Edelman JJ; Vallely MP; McCaughan BC; Jin HC; van Zandwijk N; Reid G
    J Thorac Oncol; 2013 Oct; 8(10):1317-28. PubMed ID: 24457242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications.
    Suraokar MB; Nunez MI; Diao L; Chow CW; Kim D; Behrens C; Lin H; Lee S; Raso G; Moran C; Rice D; Mehran R; Lee JJ; Pass HI; Wang J; Momin AA; James BP; Corvalan A; Coombes K; Tsao A; Wistuba II
    Ann Oncol; 2014 Jun; 25(6):1184-92. PubMed ID: 24669013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-specific genetic variants can be detected in circulating cell-free DNA of malignant pleural mesothelioma patients.
    Hylebos M; Op de Beeck K; Pauwels P; Zwaenepoel K; van Meerbeeck JP; Van Camp G
    Lung Cancer; 2018 Oct; 124():19-22. PubMed ID: 30268460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.
    Andersen M; Trapani D; Ravn J; Sørensen JB; Andersen CB; Grauslund M; Santoni-Rugiu E
    Anticancer Res; 2015 Nov; 35(11):6223-9. PubMed ID: 26504055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma.
    De Rienzo A; Archer MA; Yeap BY; Dao N; Sciaranghella D; Sideris AC; Zheng Y; Holman AG; Wang YE; Dal Cin PS; Fletcher JA; Rubio R; Croft L; Quackenbush J; Sugarbaker PE; Munir KJ; Battilana JR; Gustafson CE; Chirieac LR; Ching SM; Wong J; Tay LC; Rudd S; Hercus R; Sugarbaker DJ; Richards WG; Bueno R
    Cancer Res; 2016 Jan; 76(2):319-28. PubMed ID: 26554828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.